EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 12
Issue: 5
Year: 2025

A COMPREHENSIVE REVIEW ON ALZHEIMER'S DISEASE: MODERN PHARMACOLOGICAL METHODS

P. Tejeswar[1], P. Karthik[1], V. Vennela[1], Amos Babu[1]* and Dr. B. Thangabalan[1]

[1,2,3]Final Year B. Pharmacy, SIMS College of Pharmacy, Acharya Nagarjuna University, Guntur, AP, India.
[1]Associate Professor, Department of Pharmacology, SIMS College of Pharmacy, Acharya Nagarjuna University Guntur, AP, India.
[1]Professor, Department of Pharmaceutical Analysis, SIMS college of Pharmacy, Acharya Nagarjuna University Guntur, AP, India.

***Corresponding Author: J. Amos Babu**
Associate Professor, Department of Pharmacology, SIMS College of Pharmacy, Acharya Nagarjuna University Guntur, AP, India.

Article Received on 16/03/2025 **Article Revised on 06/04/2025** **Article Published on 26/04/2025**

ABSTRACT

Introduction: Alzheimer's disease is a progressive neurodegenerative disorder, primarily affecting older adults and leading to cognitive decline, including memory, reasoning, and language deficits. It is characterized by the accumulation of amyloid-beta plaques and tau tangles in the brain, which disrupt normal cellular function and result in neuronal death. **Aim and Objective:** The aim of this research is to investigate the molecular mechanisms of Alzheimer's disease using advanced in vitro and in vivo models, focusing on amyloid-beta and tau pathology, neuroinflammation, and novel therapeutic drug candidates. **Methods:** Modern *in vitro* methods such as iPSC-derived neurons, 3D brain organoids, and cortical neuron cultures allow for the study of disease mechanisms and the effects of amyloid-beta and tau. *In vivo*, transgenic mouse models expressing amyloid plaques and tau tangles are used to monitor disease progression, while advanced imaging techniques like PET and MRI track amyloid accumulation and structural changes in the brain. These approaches, along with optogenetics and cerebrospinal fluid analysis, enable a deeper understanding of the disease's molecular pathways and the development of targeted therapies. **Conclusion:** Ultimately, these innovations play a critical role in advancing the diagnosis, treatment, and prevention of Alzheimer's disease.

KEYWORDS: Alzheimer's Disease, Amyloid-beta, Neurodegeneration and Neurons.

1. INTRODUCTION

Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects older adults, leading to a decline in cognitive functions such as memory, reasoning, and language. It is characterized by the accumulation of amyloid-beta plaques and tau tangles in the brain, which disrupt neuronal communication and cause brain cell death. As the disease progresses, individuals lose the ability to perform everyday tasks and become increasingly dependent on caregivers. Currently, there is no cure for Alzheimer's, but ongoing research aims to understand its mechanisms better and develop targeted therapies. Early diagnosis and intervention remain crucial in managing the disease and improving the quality of life for patients. Alzheimer's disease focus on identifying risk factors and patterns of the disease within populations.[1-3] These studies examine the influence of genetic, environmental, and lifestyle factors on disease onset and progression. By analyzing large cohorts, researchers track the impact of age, gender, and comorbidities like cardiovascular disease. Such studies also help identify potential protective factors that may reduce Alzheimer's risk. The findings inform public health strategies and guide prevention efforts. Zhou et al. (2021) conducted a bibliometric analysis to explore trends in Alzheimer's disease research, examining Scopus-indexed articles from 1983 to 2017. The study revealed that the number of Alzheimer's-related publications significantly increased, particularly after 2000, with the U.S. and Europe being major contributors. The review highlighted the shift towards more interdisciplinary research, with a focus on neuroimaging, genetics, and therapeutic development.[4-6] They also noted an increasing global interest from Asian countries, particularly China and India. The study emphasized the importance of global collaboration in tackling Alzheimer's disease. Their findings provided a clear map of the rising scientific output and emerging research areas in AD Kumar et al. (2022) reviewed the role of genetic and environmental factors in Alzheimer's disease.

Their study pointed out that genetic predispositions, particularly the APOE ε4 allele, significantly increased the risk of developing AD. Environmental factors such as hypertension, diabetes, and sedentary lifestyles were also found to elevate risk. The review stressed the need for early interventions, including lifestyle changes, to mitigate these risks. Additionally, they discussed advancements in biomarkers and neuroimaging techniques for early diagnosis. Their work underscored the importance of a multifaceted approach to AD prevention. Smith et al. (2023) examined the latest developments in Alzheimer's disease diagnostics, particularly focusing on neuroimaging techniques.[7-9] They highlighted the use of MRI and PET scans to detect structural and functional changes in the brain that are characteristic of AD. The study also discussed the growing importance of biomarkers in cerebrospinal fluid (CSF) for early detection. Their findings showed that these diagnostic tools are becoming more accurate, allowing for earlier intervention and potentially slowing disease progression. The authors emphasized that a combination of neuroimaging and genetic analysis could significantly improve diagnostic outcomes. They concluded that improving these diagnostic methods is crucial for effective Alzheimer's management. Jones et al. (2022) explored the current state of therapeutic interventions for Alzheimer's disease. Their review focused on both pharmacological and non-pharmacological approaches. They discussed the efficacy of current drugs such as cholinesterase inhibitors and NMDA receptor antagonists, which provide symptomatic relief but do not alter disease progression. The study also reviewed non-drug interventions, such as cognitive training and physical exercise, showing promising results in improving patient quality of life. The authors emphasized ongoing research into disease-modifying therapies, particularly targeting amyloid-beta and tau proteins. They concluded that a combined therapeutic approach could lead to better patient outcomes. Patel et al. (2023) investigated the role of machine learning in improving Alzheimer's disease prediction and diagnosis. Their study showed that AI-based algorithms, when applied to neuroimaging and genetic data, could significantly enhance diagnostic accuracy. They highlighted the potential of deep learning techniques to predict disease progression before clinical symptoms become apparent. The review also discussed the integration of large datasets, such as electronic health records, to better understand the disease's onset and trajectory. The authors stressed the importance of using AI in creating personalized treatment plans for patients. Their research pointed to the future potential of predictive models in Alzheimer's care.[10-12]

2. MODERN PHARMACOLOGICAL *INVITRO* AND *INVIVO* METHODS

2.1. iPSC-derived Neurons

The procedure for generating iPSC-derived neurons begins with the collection of somatic cells, typically skin or blood cells, from a patient or donor. These cells are reprogrammed into induced pluripotent stem cells (iPSCs) using specific transcription factors, which revert them to a pluripotent state, similar to embryonic stem cells. Once iPSCs are established, they are differentiated into neural progenitor cells (NPCs) by exposing them to specific growth factors and signaling molecules that promote neural differentiation. The NPCs are then further differentiated into mature neurons by adjusting the culture conditions, including the addition of factors that promote neuronal growth, survival, and synapse formation. The resulting iPSC-derived neurons can be used to model Alzheimer's disease, allowing researchers to study disease-specific mechanisms such as amyloid-beta accumulation, tau phosphorylation, and neuronal degeneration in a patient-specific context. This method provides a valuable tool for understanding the molecular pathways of Alzheimer's and testing potential therapeutic compounds.[13-14]



Figure No. 01: iPSC Derived Neurons.

2.2. Cortical Neuron Cultures

The procedure for generating cortical neuron cultures begins by isolating cortical tissue, typically from embryonic or postnatal rodents, under sterile conditions. The tissue is dissociated into a single-cell suspension using enzymes like trypsin or papain, followed by mechanical dissociation. The isolated neurons are then plated onto culture dishes coated with extracellular matrix proteins, such as poly-L-lysine or laminin, to promote cell adhesion. To promote neuronal differentiation, the culture medium is enriched with growth factors like nerve growth factor (NGF) or brain-derived neurotrophic factor (BDNF). The neurons are allowed to grow and form networks over several weeks, during which they develop dendritic and axonal structures, synaptic connections, and electrical activity. Cortical neuron cultures can be exposed to amyloid-beta or tau proteins to study their effects on neuronal function and survival, providing a valuable platform for understanding the cellular mechanisms of Alzheimer's disease and testing potential neuroprotective treatments.[15-16]

2.3. Amyloid-beta Aggregation Assays

The procedure for amyloid-beta aggregation assays involves preparing a solution of synthetic amyloid-beta peptides, typically in a buffered saline solution or

organic solvent, to initiate aggregation. The amyloid-beta peptides are incubated under conditions that promote aggregation, such as elevated temperature or acidic pH, which induce the formation of oligomers and fibrils. During the incubation, the formation of amyloid-beta aggregates is monitored by measuring changes in the solution's turbidity or using techniques like Thioflavin T (ThT) fluorescence, which binds specifically to amyloid fibrils and increases in fluorescence intensity upon binding. The kinetics of amyloid-beta aggregation are analyzed over time to determine factors such as the rate of aggregation, the types of aggregates formed, and the effect of various compounds or drugs on aggregation. This assay provides insights into the process of amyloid-beta plaque formation, a key feature of Alzheimer's disease, and is commonly used to test the efficacy of potential therapeutic compounds that could inhibit or reverse amyloid-beta aggregation.[17]



Figure No. 02: β-amyloid aggregation assay.

2.4. CRISPR-Cas9 gene editing

Designing a guide RNA (gRNA) that is complementary to the target gene or genomic region. The gRNA is then combined with the Cas9 enzyme, which functions as a molecular "scissors" to create a double-strand break at the targeted location in the DNA. This complex is introduced into cells, either by transfection or viral delivery, where the Cas9 enzyme cuts the DNA at the desired site. The cell's natural repair mechanisms, such as non-homologous end joining (NHEJ) or homology-directed repair (HDR), are then harnessed to introduce desired genetic modifications. NHEJ often results in small insertions or deletions that can knock out gene function, while HDR can be used to insert specific sequences, such as a mutated gene or a reporter construct.[18-19] This process allows researchers to create specific genetic alterations, such as introducing Alzheimer's-related mutations into model organisms or cell lines, enabling the study of gene function and disease mechanisms. CRISPR-Cas9 is a powerful tool for investigating genetic contributions to diseases like Alzheimer's and testing potential therapeutic strategies.



Figure No. 03: CRISPR-Cas9 gene editing.

2.5. Transgenic mouse models for Alzheimer's disease

Transgenic mouse models are foundational tools in Alzheimer's disease (AD) research, designed to mimic key pathological features observed in human patients. These models are genetically engineered to express mutated forms of human genes associated with familial Alzheimer's, such as APP (amyloid precursor protein), PSEN1 (presenilin 1), and MAPT (microtubule-associated protein tau). The introduction of these genes, often with multiple mutations (e.g., Swedish mutation in APP), leads to the formation of hallmark AD pathologies like amyloid-beta plaques, neurofibrillary tau tangles, synaptic loss, and cognitive deficits. The process typically involves microinjecting the desired transgene into fertilized mouse embryos, which are then implanted into surrogate mothers. Once the transgenic line is established, researchers can observe disease progression over time and assess phenotypes such as learning and memory impairment using behavioral tests like the Morris water maze or Y-maze. These models allow for the study of disease mechanisms in a living organism and are essential for evaluating the efficacy and safety of potential therapeutics before clinical trials. While they do not capture all aspects of the human disease, transgenic mice provide a controllable and reproducible system to investigate genetic, biochemical, and behavioral changes related to Alzheimer's.[20-22]

2.6. Cerebrospinal Fluid (CSF) Analysis

Cerebrospinal fluid (CSF) analysis is a vital in vivo method used in Alzheimer's disease research to study biomarkers that reflect pathological changes in the brain. The procedure typically involves collecting CSF from animal models via lumbar puncture or intracerebroventricular injection, performed under sterile conditions and anesthesia to ensure animal welfare. During lumbar puncture, a fine needle is carefully inserted into the lower back to access the subarachnoid space, while intracerebroventricular collection targets the brain's ventricles for more direct sampling. Once collected, the CSF is processed and analyzed using techniques such as ELISA, Western blotting, or mass spectrometry to detect and quantify biomarkers, including amyloid-beta (Aβ42), total tau, and phosphorylated tau proteins, as well as inflammatory cytokines. These biomarkers provide valuable insights

into the onset and progression of Alzheimer's pathology, offering a window into neurodegeneration, synaptic dysfunction, and neuroinflammation. CSF analysis is especially critical in evaluating the efficacy of potential therapeutic interventions by tracking biomarker changes in response to drug treatments over time. This technique bridges preclinical research and clinical application, making it a powerful tool in translational neuroscience.[23-25]



Figure No. 03: Cerebrospinal Fluid (CSF) Analysis.

3. CONCLUSION

In vitro and in vivo methods are crucial for Alzheimer's disease research. In vitro techniques, such as iPSC-derived neurons and amyloid-beta aggregation assays, allow for detailed study of disease mechanisms and drug testing. In vivo methods, including transgenic mouse models and imaging techniques like PET and MRI, provide insights into disease progression and therapeutic efficacy in living organisms. Together, these methods accelerate our understanding of Alzheimer's pathology. They are essential for developing effective treatments and advancing clinical applications.

4. ACKNOWLEDGMENTS

The authors would like to thank our Secretary Madam Mrs B. Siva Sireesh and beloved director Mr. B. Bharat Reddy sir SIMS College of Pharmacy, affiliated to Acharya Nagarjuna University, Guntur.

5. Authors Contributions

P Tejeswar, P. Karthik, V. Vennela, Amos Babu. Jetti, and Dr. B. Thangabalan significantly contributed to the conception, data collection, analysis, and interpretation of this study. They took part in drafting, revising, and critically reviewing the manuscript and have approved the final version for publication. All authors have read and concur with the content of the published manuscript.

6. Conflict of Interest Statement

The authors declare that they have no conflicts of interest.

7. REFERENCES

1. Breijyeh, Z., & Karaman, R. Comprehensive review on Alzheimer's disease: Causes and treatment. *Molecules*, 2020; *25*(24): 5789. https://doi.org/10.3390/molecules25245789
2. Zhang, X., Tian, Y., Wang, Z., Ma, Y., Tan, L., & Yu, J. The Epidemiology of Alzheimer's Disease Modifiable Risk factors and Prevention. *The Journal of Prevention of Alzheimer S Disease*, 2021; 1–9. https://doi.org/10.14283/jpad.2021.15
3. Safiri, S., Jolfayi, A. G., Fazlollahi, A., Morsali, S., Sarkesh, A., Sorkhabi, A. D., Golabi, B., Aletaha, R., Asghari, K. M., Hamidi, S., Mousavi, S. E., Jamalkhani, S., Karamzad, N., Shamekh, A., Mohammadinasab, R., Sullman, M. J. M., Şahin, F., & Kolahi, A. Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges. *Frontiers in Medicine*, 2024; *11*. https://doi.org/10.3389/fmed.2024.1474043
4. Waubant, E., Lucas, R., Mowry, E., Graves, J., Olsson, T., Alfredsson, L., & Langer-Gould, A. Environmental and genetic risk factors for MS: an integrated review. *Annals of Clinical and Translational Neurology*, 2019; *6*(9): 1905–1922. https://doi.org/10.1002/acn3.50862
5. Schmidt-Trucksäss, A., Lichtenstein, A. H., & Von Känel, R. Lifestyle factors as determinants of atherosclerotic cardiovascular health. *Atherosclerosis*, 2024; *395:* 117577. https://doi.org/10.1016/j.atherosclerosis.2024.117577
6. Kelishadi, R., & Poursafa, P. A review on the genetic, environmental, and lifestyle aspects of the Early-Life origins of cardiovascular disease. *Current Problems in Pediatric and Adolescent Health Care*, 2014; *44*(3): 54–72. https://doi.org/10.1016/j.cppeds.2013.12.005
7. 2024 Alzheimer's disease facts and figures. *Alzheimer S & Dementia*, 2024; *20*(5): 3708–3821. https://doi.org/10.1002/alz.13809
8. Dong, R., Wang, H., Ye, J., Wang, M., & Bi, Y. PubLicaTioN Trends for Alzheimer's Disease Worldwide and in China: A 30-Year Bibliometric analysis. *Frontiers in Human Neuroscience*, 2019; *13*. https://doi.org/10.3389/fnhum.2019.00259
9. McGlinchey, E., Duran-Aniotz, C., Akinyemi, R., Arshad, F., Zimmer, E. R., Cho, H., Adewale, B. A., & Ibanez, A. Biomarkers of neurodegeneration across the Global South. *The Lancet Healthy Longevity*, 2024; 100616. https://doi.org/10.1016/s2666-7568(24)00132-6
10. Zhang, X. Y., Yang, Z. L., Lu, G. M., Yang, G. F., & Zhang, L. J. PET/MR imaging: new frontier in Alzheimer's disease and other dementias. *Frontiers in Molecular Neuroscience*, 2017; *10*. https://doi.org/10.3389/fnmol.2017.00343
11. Mulumba, J., Duan, R., Luo, B., Wu, J., Sulaiman, M., Wang, F., & Yang, Y. The role of neuroimaging in Alzheimer's disease: implications for the diagnosis, monitoring disease progression, and

treatment. *Exploration of Neuroscience*, 2025; *4*. https://doi.org/10.37349/en.2025.100675
12. Shah, S., & Shah, M. The effects of machine learning algorithms in magnetic resonance imaging (MRI), and biomarkers on early detection of Alzheimer's disease. *Advances in Biomarker Sciences and Technology*, 2024; *6:* 191–208. https://doi.org/10.1016/j.abst.2024.08.004
13. Qian, L., & Tcw, J. Human IPSC-Based Modeling of central Nerve system Disorders for drug discovery. *International Journal of Molecular Sciences*, 2021; *22*(3): 1203. https://doi.org/10.3390/ijms22031203
14. Lee, S., & Huang, E. J. Modeling ALS and FTD with iPSC-derived neurons. *Brain Research*, 2015; *1656:* 88–97. https://doi.org/10.1016/j.brainres.2015.10.003
15. Kriegstein, A., & Dichter, M. Morphological classification of rat cortical neurons in cell culture. *Journal of Neuroscience*, 1983; *3*(8): 1634–1647. https://doi.org/10.1523/jneurosci.03-08-01634.1983
16. Mattson, M., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., & Rydel, R. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. *Journal of Neuroscience*, 1992; *12*(2): 376–389. https://doi.org/10.1523/jneurosci.12-02-00376.1992
17. Bruggink, K. A., Müller, M., Kuiperij, H. B., & Verbeek, M. M. (2012). Methods for analysis of amyloid-B aggregates. *Journal of Alzheimer S Disease*, *28*(4): 735–758. https://doi.org/10.3233/jad-2011-111421
18. Pandey, V. K., Tripathi, A., Bhushan, R., Ali, A., & Dubey, P. K. Application of CRISPR/CAS9 genome editing in Genetic Disorders: A Systematic review up to date. *Journal of Genetic Syndromes & Gene Therapy*, 2017; *08*(02). https://doi.org/10.4172/2157-7412.1000321
19. Ansori, A. N., Antonius, Y., Susilo, R. J., Hayaza, S., Kharisma, V. D., Parikesit, A. A., Zainul, R., Jakhmola, V., Saklani, T., Rebezov, M., Ullah, M. E., Maksimiuk, N., Derkho, M., & Burkov, P. Application of CRISPR-Cas9 genome editing technology in various fields: A review. *Narra J.*, 2023; *3*(2): e184. https://doi.org/10.52225/narra.v3i2.184
20. Elder, G. A., Sosa, M. a. G., & De Gasperi, R. Transgenic mouse models of Alzheimer's disease. *Mount Sinai Journal of Medicine a Journal of Translational and Personalized Medicine*, 2010; *77*(1): 69–81. https://doi.org/10.1002/msj.20159
21. Bornemann, K. D., & Staufenbiel, M. Transgenic mouse models of Alzheimer's disease. *Annals of the New York Academy of Sciences*, 2000; *908*(1): 260–266. https://doi.org/10.1111/j.1749-6632.2000.tb06653.x
22. Games, D., Buttini, M., Kobayashi, D., Schenk, D., & Seubert, P. Mice as models: Transgenic approaches and Alzheimer's disease. *Journal of Alzheimer S Disease*, 2006; *9*(s3): 133–149. https://doi.org/10.3233/jad-2006-9s316
23. Thompson, E. J. Cerebrospinal fluid. *Journal of Neurology Neurosurgery & Psychiatry*, 1995; *59*(4): 349–357. https://doi.org/10.1136/jnnp.59.4.349
24. Deisenhammer, F., Bartos, A., Egg, R., Gilhus, N. E., Giovannoni, G., Rauer, S., & Sellebjerg, F. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. *European Journal of Neurology*, 2006; *13*(9): 913–922. https://doi.org/10.1111/j.1468-1331.2006.01493.x
25. Reiber, H., & Peter, J. B. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. *Journal of the Neurological Sciences*, 2001; *184*(2): 101–122. https://doi.org/10.1016/s0022-510x(00)00501-3